Celldex Therapeutics welcomes Cheryl Cohen and Dr. Garry Neil to its Board of Directors

– USA, NJ –  Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the appointments of Cheryl Cohen and Dr. Garry Neil to its Board of Directors.

“We are thrilled to welcome Cheryl and Garry to our Board of Directors during an important time for Celldex. Their combined expertise brings well rounded experience to provide guidance as we progress our clinical and corporate goals. I am confident that they will offer valuable perspectives as we continue to execute our development strategy,” said Co-founder and CEO, Tony Marucci.

About Cheryl L. Cohen

Cheryl Cohen has served as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm that specializes in new product start-ups and commercialization. From August 2011 to July 2014, Ms. Cohen served as CCO of Medivation, Inc., where she built the company’s commercial organization and lead her team to successfully launch the oncology drug, Xtandi. Before joining Medivation, Ms. Cohen spent over ten years at Johnson & Johnson, most notably as VP of the Rheumatology Franchise. Ms. Cohen began her career at Solvay Pharmaceuticals in management and sales. Ms. Cohen currently serves on the Board of Directors of MEI Pharma, Immunity Bio, and Ignyte Acquisition Corp., all of which are publicly traded companies.

She earned a B. A. degree from Saint Joseph College.

About Dr. Garry Neil

Dr. Neil has served as CEO at Avalo Therapeutics, a publicly held biotechnology company. Before that, Dr. Neil was Senior Scientific Adviser and CSO at Avalo since its February 2020 merger with Aevi Genomic Medicine, Inc., a biotechnology company where Dr. Neil had served as CSO from September 2013 to February 2020. Before joining Aevi, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held several senior positions in the pharmaceutical industry, including most recently Corporate VP of Science & Technology at Johnson & Johnson from November 2007 to August 2012. Before these roles, Dr. Neil served as Group President at Johnson & Johnson Pharmaceutical Research and Development, VP of Research & Development at Merck KGaA/EMD Pharmaceuticals, and VP of Clinical Research at AstraZeneca and Astra Merck. Dr. Neil has served on the Board of Directors of Arena Pharmaceuticals, Inc. since February 2017 and as its Chair since February 2021. From August 2016 to May 2019, he previously served on the board of GTx, Inc., a publicly-traded biopharmaceutical company. He is a member of the board of the Center for Discovery and Innovation of the Hackensack Meridian Medical School in Hackensack, New Jersey, and is the Founding Chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry Research & Development consortium, and is a past member of the TransCelerate Board from 2012 to 2019. He served on the board of Reagan Udall Foundation for the FDA from 2007 – 2021, the board of Foundation for the National Institutes of Health from 2010 – 2012, and the Science Management Review Board of the NIH from 2010 – 2012. Dr. Neil is also the past Chairman of the Pharmaceutical Research and Manufacturers Association Science and Regulatory Executive Committee and the PhRMA Foundation board.

Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic.

About Celldex Therapeutics, Inc.

Celldex is a clinical-stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

For more information: https://celldex.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team